LB Pharmaceuticals On Track For Phase 3 NOVA-2 LB-102 Schizophrenia Topline Data In 1H27; Cash $403.8M Funds Operations Beyond Q2 2029
Share
Why It Matters
LB Pharma is testing a new schizophrenia medicine and has enough cash to keep going. Watch if their medicine works well when they share results next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.